Activation of macrophage nuclear factor-κB and induction of inducible nitric oxide synthase by LPS by Li, Ying-Hua et al.
Available online http://respiratory-research.com/content/3/1/23
Page 1 of 6
(page number not for citation purposes)
Respiratory Research  Vol 3 No 1 http://respiratory-research.com/content/3/1/23 Li et al. Research article
Activation of macrophage nuclear factor-κ B and induct
ion of inducible nitric oxide synthase by LPS
Ying-Hua Li1,2, Zhong-Qun Yan3, Annelie Brauner2 and Kjell Tullus1
1Astrid Lindgren Children's Hospital, Karolinska Institutet, Stockholm, Sweden
2Department of Clinical Microbiology, Karolinska Hospital, Stockholm, Sweden
3Center for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden
Correspondence: Ying-Hua Li - Ying-Hau.Li@kbh.ki.se
Abstract
Background: Chronic lung disease (CLD) of prematurity is a major problem of neonatal care. Bacterial
infection and inflammatory response have been thought to play an important role in the development of
CLD and steroids have been given, with some benefit, to neonates with this disease. In the present
study, we assessed the ability of lipopolysaccharide (LPS) to stimulate rat alveolar macrophages to
produce nitric oxide (NO), express inducible nitric oxide synthase (iNOS) and activate nuclear factor-
κ B (NF-κ B) in vitro. In addition, we investigated the impact of dexamethasone and budesonide on these
processes.
Methods: Griess reaction was used to measure the nitrite level. Western blot and a semi-quantitative
RT-PCR were performed to detect iNOS expression. Electrophoretic mobility shift assay (EMSA) was
performed to analyze the activation of NF-κ B.
Results: We found that LPS stimulated the rat alveolar macrophages to produce NO in a dose (≥ 10
ng/ml) and time dependent manner (p < 0.05). This effect was further enhanced by IFN-γ  (≥ 10 IU/ml,
p < 0.05), but was attenuated by budesonide (10-4–10-10 M) and dexamethasone (10-4–10-6 M) (p <
0.05). The mRNA and protein levels of iNOS were also induced in response to LPS and attenuated by
steroids. LPS triggered NF-κ B activation, a mechanism responsible for the iNOS expression.
Conclusion: Our findings imply that Gram-negative bacterial infection and the inflammatory responses
are important factors in the development of CLD. The down-regulatory effect of steroids on iNOS
expression and NO production might explain the beneficial effect of steroids in neonates with CLD.
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Introduction
Chronic lung disease (CLD) of prematurity, previously de-
scribed as bronchopulmonary dysplasia by Northway and
co-workers in 1967 [1], is a prolonged respiratory illness
often needing long-time care such as prolonged ventilation,
with up to one years oxygen dependency. The definition of
CLD was later modified to encompass all forms of acute
pulmonary injury during the first week of life, leading to a de-
pendency on supplemental oxygen at a later stage (36
weeks of postconceptional age). The etiology of CLD is
multifactorial and not fully understood. The development of
CLD is characterized by an initial increase of inflammatory
cells [2] and mediators [3,4]. Extensive release of proin-
flammatory cytokines, lipid mediators and other inflammato-
ry mediators in neonates seems to play an important role in
the maintenance of the inflammatory response in premature
infants [2,5]. During later phases there is a dominance of
lung fibrosis.
Administration of steroids to infants with CLD, or those at
high risk of developing CLD, leads to an improvement in
pulmonary mechanics and gas exchange facilitating the
discontinuation of mechanical ventilation and possibly re-
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ducing the duration of oxygen therapy and the incidence of
severe CLD [6].
Nitric oxide (NO) is generated from L-arginine by three dif-
ferent NO synthases. Of these, two are constitutive isofor-
ms; the third, inducible and Ca2+-independent NO
synthase (iNOS), is expressed only following transcription-
al activation of its gene [7,8], as in acute and chronic inflam-
mation [9]. Biosynthesis of NO protein and iNOS mRNA
has been increasingly recognized as an important intra- and
intercellular messenger molecule in vascular relaxation,
platelet activation and immune response [10] in human
mononuclear cells. It plays important roles in the pathogen-
esis of Gram-negative septic shock and other infectious
diseases [11]. High levels of NO produced by iNOS can
mediate lung injury [12]. Laboratory studies have suggest-
ed that NO can potentiate lung injury by promoting oxida-
tive or nitrosative stress [13], inactivating surfactant, and
stimulating inflammation [14].
NF-κ B is a ubiquitous transcription factor that is responsi-
ble for the gene expression of, for example, cytokines,
chemokines, growth factors, cell adhesion molecules and
some acute phase proteins. There are five mammalian NF-
κ B family members which include NF-κ B1 (p50/p105), NF-
κ B2 (p52/p100), p65 (RelA), RelB, and c-Rel [15].
Infectious agents, predominantly Gram-negative bacteria,
are thought to be one of the major causes of neonatal lung
injury [2,16]. We therefore hypothesized that lipoplysac-
charide (LPS), the major component of Gram-negative bac-
teria, activates alveolar macrophage NF-κ B, induces
expression of iNOS and increases NO production. We in-
vestigated whether steroids could attenuate this inflamma-
tory response.
Materials and methods
Cell culture
A rat alveolar macrophage cell line (ATCC 8383, Rockville,
Maryland, USA) was maintained in Ham's F-12 medium
(GibcoBRL, Gaithersburg, MD, USA) and supplemented
with 15% heat-inactivated fetal bovine serum (GibcoBRL).
The limulus amebocyte lysate (LAL)(Charles River En-
dosafe, SC, USA) test in the reagents showed that the en-
dotoxin level was less than 10 pg/ml.
Study protocol
Rat alveolar macrophages were distributed into 24 micro-
well plates at a concentration of 1 ×  106 cells/ml in serum
and phenol free medium and stimulated with 10–1000 ng/
ml of LPS, O55:B5 (Sigma, St. Louis, Missouri, USA) or in
combination with 1–100 IU/ml IFN-γ  (Genzyme, Cam-
bridge, MA, USA) for 24 hours at 37°C with 5% CO2. To
evaluate the role of steroids, rat macrophages were incu-
bated with 100 ng/ml of LPS in the presence of dexameth-
asone (10-4–10-10 M) or budesonide (10-4–10-10 M).
Nitrite assay
All the supernatants were collected after stimulation and
stored at -70°C for analysis of NO. The accumulation of
NO2
-, a stable end product of NO formation, in conditioned
media was measured as an indicator of NO production.
100 µl cell-free conditioned medium was incubated for 10
min with 100 µL Griess reagent at room temperature and
the absorbance at 540 nm was measured in a microplate
reader. NO2
- in the samples was calculated from a stand-
ard curve of sodium nitrite.
Western blot analysis
Macrophages were lysed with Laemmli sample buffer and
denatured by boiling for 5 min. The protein concentration
was determined using a bicinchonic acid kit (Pierce, Oud
Beijerlands, The Netherlands). For western blot analysis,
10 µg of protein per lane was separated on 7.5% SDS-
polyacrylamide gels, and electroblotted on hydrophobic
polyvinylidene difluoride (PVDF) membranes (Amersham,
Buckinghamshire, UK). The membrane was blocked in 5%
non-fat dry milk dissolved in TTBS (Tween tris buffered sa-
line) (150 mM NaCl, 10 mM Tris-HCl and 0.1% Tween-20,
pH 7.4), and subsequently incubated for 1 hour at room
temperature with a monoclonal antibody against macro-
phage iNOS (Transduction Lab, Lexington, KY, USA), fol-
lowed by incubation for 1 hour with horseradish
peroxidase-conjugated sheep anti-mouse Ig F(ab') frag-
ments (Amersham). Immunoreactive bands were visualized
using an enhanced chemiluminescence kit (Amersham).
RT-PCR
Total RNA was extracted from cells with RNAzol™B (Bio-
tecx Laboratories, Houston, TX, USA), after the different
treatments, according to the manufacturer's instructions.
First strand cDNA synthesis of total RNA was performed
using SuperScript RNase H- Reverse Transcriptase (Gib-
coBRL) and random hexamer primers (pd(N)6; Amersham
Pharmacia Biotech, Uppsala, Sweden). Specific oligonu-
cleotide primers were synthesized for rat iNOS (Clontech,
Palo Alto, CA, USA). The sequences of the 3'- and 5'-prim-
ers used were CCCTTCCGAAGTTTCTGGCAGCAG and
GGGCTCCTCCAAGGTGTTGCCC [17]. The rat G3PDH
primers were obtained from Innovagen (Lund, Sweden).
The sequences were CTCAAGATTGTCAGCAATGC and
CAGGATGCCCTTTAGTGGGC [18]. The PCR using Taq
polymerase (final concentration 0.025 U/µl; GibcoBRL)
was performed at a final volume of 25 µl containing 2 µl of
cDNA for iNOS and G3PDH in a DNA Thermocycler 480
(Perkin Elmer, Norwalk, CT, USA) for 33 cycles for rat
iNOS under the following conditions: 1 min denaturation at
94°C, 1 min annealing at 60° and 2 min extension at 72°C.
PCR was conducted for rat G3PDH for 1 min at 94°C, 1Available online http://respiratory-research.com/content/3/1/23
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min at 60°C and 1 min at 72°C. The PCR products were
separated on a 1.5 % agarose gel (GibcoBRL). The ethid-
ium bromide stained gel was photographed under UV-light
with the DC120 Digital Zoom Camera (Eastman Kodak
Company, Rochester, NY, USA) and the net intensities of
the PCR products were analyzed with the Kodak Digital
Science™ Electrophoresis Documentation and Analysis
System 120 (Eastman Kodak).
Electrophoretic mobility shift assay (EMSA)
Cells grown in serum-free medium were stimulated with 4
×  108 CCU/ml of LPS for 30 min or preteated with dexam-
ethasone (10-4 M) or budesonide (10-4 M) for 1 hour. Nu-
clear extracts were prepared as described [19] and nuclear
protein concentrations determined using the BCA (bicin-
choninic acid) method (Pierce, Rockford, IL). The nuclear
extract (3 µg of protein) was preincubated for 10 min in the
reaction buffer (10 mM HEPES, pH 7,9, 10% glycerol, 60
mM KCl, 5 mM MgCl2, 0.5 mM EDTA, 1 mM DTT, 1 mM
phenylmethylsulfonyl fluoride (PMSF) and 2 mg poly (dI-
dC)) (deoxyinosinate-deoxycytidylate) followed by incuba-
tion for 30 min at room temperature with 50,000 cpm of
32P-labeled NF-κ B probe (double-stranded oligonucle-
otides containing an NF-κ B consensus binding site: 5'-
AGT TGA GGG GAC TTT CCC AGG C-3', [Promega,
Madison, WI, USA]). After 30 min at room temperature,
samples were separated on 4% native polyacrylamide gels
in low ionic strength buffer (22.3 mM Tris-borate, 0.5 mM
EDTA, pH 8). Dried gels were autoradiographed with inten-
sive screens at -80°C. In some cases, the incubation of nu-
clear extracts with 32P-labeled NF-κ B probe was
performed in the presence of 25 and 50 times excess un-
labeled NF-κ B probe or unlabeled irrelevant oligonucle-
otide probe for AP-1 (Promega). For supershift analysis,
rabbit anti-p50 and anti-p65 polyclonal antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA) were incubated with
the nuclear extracts for 15 min prior to the addition of radi-
olabeled probe.
Statistical evaluation
Data from pooled experiments were reported as the mean
nitrite concentrations ± the standard errors of the means
(SEMs). Data were analyzed by one-way ANOVA test fol-
lowed by Newman-Keuls test for two mean comparisons. A
P value of less than 0.05 was considered to be significant.
Results
LPS stimulated NO production and iNOS expression
After treatment with LPS, the alveolar macrophage pro-
duced NO in a dose and time dependent fashion (Fig. 1A
&1B). LPS at concentrations ≥ 10 ng/ml induced the pro-
duction of NO (p < 0.05) at 24 hours. This effect could be
further enhanced in the presence of IFN-γ  (10–100 IU/ml,
p < 0.05) (Fig. 1C). The induced NO production could be
detected in the conditioned media after 6 hours stimulation
with LPS and reached peak levels at 24 hours in our time
setting.
Since iNOS is regulated mainly at the transcriptional level,
we further checked iNOS transcripts by a semi-quantitative
RT-PCR. Abundant iNOS mRNA was found in the LPS
stimulated cells at 24 hours compared to untreated cells
(Fig. 2). The protein of iNOS showed the same pattern in
the LPS stimulated cells determined by western blot (Fig.
3).
Down-regulation of NO production and iNOS expression 
by steroids
Budesonide (10-4–10-10 M) and dexamethasone (10-4–
10-6 M) significantly inhibited NO production stimulated by
LPS in the rat alveolar macrophages (p < 0.05) (Fig. 1D)
and the effect was regulated at the transcript level deter-
mined by RT-PCR (Fig. 2) and western blot (Fig. 3)
NF-κ B activation
The effect of LPS on the NF-κ B signal tranduction pathway
in alveolar macrophages was determined by EMSA. After
treatment of macrophages with LPS for 30 min a substan-
tially enhanced NF-κ B binding complex was observed in
the nuclear extract of macrophages (Fig. 4). The specificity
of the NF-κ B-DNA complex was ascertained by competi-
tion study. As shown in Fig. 4, the indicated NF-κ B-DNA
complexes were substantially removed by adding an ex-
cess of cold NF-κ B probe but were not affected by adding
excess unlabelled AP-1 probe.
Discussion
We demonstrated that LPS could trigger rat alveolar mac-
rophages to express iNOS and thus produce NO in a dose
and time-dependent fashion. This induction was significant-
ly enhanced in the presence of IFN-γ  and inhibited by ster-
oids. Moreover, LPS was capable of activating NF-κ B.
Clinical studies have suggested that NO is an important in-
flammatory mediator in several human infections especially
in fulminant early-onset neonatal pneumonia [20], sepsis
and Leishmania infantum infection [21–23]. Likewise,
monocytes and tissue macrophages isolated from patients
with rheumatoid arthritis, tuberculosis and malaria display
higher levels of iNOS and generate increased levels of NO
in vitro[11]. It is known that there are species differences of
NO production. Weinberg [11] has reviewed the reports
from 1989 to 1998 regarding NO production and iNOS ex-
pression in human mononuclear phagocytes where there
were some difficulties in detecting NO production, partly
depending on the method used. Rodent mononuclear
phagocytes have been used for many in vitro studies
[24,25], mainly because they seem to be more sensitive.
NF-κ B is known as a widespread rapid response transcrip-
tion factor expressed in a variety of cells [26]. Both endog-Respiratory Research   Vol 3 No 1   Li et al.
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enous and exogenous stimuli induce NF-κ B activation. The
role of NF-κ B in iNOS gene expression has been well elu-
cidated [27]. Using transfection techniques Xie and col-
leagues showed that activation of NF-κ B is an essential
mechanism responsible for LPS – or oxidative stress-in-
duced NO production in mouse macrophages [28]. Our
data demonstrate that LPS is a potent activator of NF-κ B in
rat alveolar macrophages, as evidenced by its rapid and in-
tense NF-κ B activation. This indicates that NF-κ B activa-
tion may be of great importance for the LPS induced iNOS
expression in our study. In addition, the potential role of NF-
κ B in inflammation and immune modulation in Gram-nega-
tive bacterial infections is not limited to transcriptional acti-
vation of iNOS. In fact, it has been shown that NF-κ B plays
a crucial role in the inducible expression of many inflamma-
tory genes encoding transcriptional factors, adhesion mol-
ecules, cytokines and growth factors [15]. Therefore, LPS
induced NF-κ B activation in macrophages may represent a
key mechanism responsible for the inflammatory reaction
that is important in the development of CLD caused by
Gram-negative bacteria.
Although the physiologic production of NO plays a key role
in host defense against various intracellular pathogens, its
overproduction may be responsible in part for the patho-
physiology of infection [29]. Overproduction of NO is likely
to contribute to the hemodynamic instability in overwhelm-
ing sepsis in humans [30]. Animal studies suggest that the
high-output NO pathway is responsible for escalating the
inflammatory response [31]. When the production of NO is
left unattenuated, especially under oxidative stress, direct
cytotoxic effects of NO can emerge through the formation
of peroxynitrite, as a result of a reaction between NO and
superoxide [13], which is an important mediator of tissue
injury and organ dysfunction [9]. The oxidative stress, DNA
damage and disruption caused by excess NO can lead to
cell death by apoptosis or necrosis [32]. It is thus likely that
when the preterm infant is infected with bacteria in the
lungs, alveolar macrophages and lymphocytes will infiltrate
and result in elevated levels of NO, cytokines such as TNF-
α , IL-6 and IL-8 [5,33–35] and other inflammatory media-
tors, which may lead to lung tissue injury and fibrosis.
Inhibiting high-output NO production by blocking iNOS ex-
pression/activity may be a useful strategy in the treatment
Figure 1
A. LPS induced NO production by alveolar macrophages. Macrophages were stimulated with LPS (10–1000 ng/ml) for 24 hours. B. Kinetics of NO
production by macrophages in response to and LPS (100 ng/ml). C. LPS (100 ng/ml) in combination with IFN-γ  (1–100 IU/ml) in macrophages. D.
Downregulation of LPS (100 ng/ml) stimulated NO production in the rat alveolar macrophage cell line by different doses of budesonide and dexam-
ethasone. NO production was assessed by determining NO2
- concentration in conditioned medium. LPS = lipopolysaccharide; IFN-γ  = gamma
interferon.
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of inflammatory disorders such as CLD. We have shown
that both budesonide and dexamethasone can down-regu-
late iNOS expression causing decreased NO production at
the inflammatory site. This can perhaps partly explain why
steroids have a beneficial effect in the treatment of CLD in
neonates.
It seems that steroids have a stronger effect on NO produc-
tion than on iNOS mRNA expression. The observed differ-
ence could be caused by the influence of steroids on
different steps. One is to inhibit iNOS at the transcription
level through inactivation of the NF-κ B pathway. Steroids
may also have a direct effect on iNOS protein expression
and further influence the NO production.
Conclusion
Our study showed that LPS activates NF-κ B, induces the
iNOS expression and further enhances the NO production
in macrophages, which might imply that Gram-negative
bacteria are important etiological factors in the develop-
ment of CLD.
Figure 2
LPS induced expression of iNOS mRNA in the alveolar macrophages.
Macrophages were stimulated with LPS at 100 ng/ml for 24 hours and
mRNA was determined by RT-PCR. The iNOS mRNA was inhibited in
the presence of budesonide (10-4 M) and dexamethasone (10-4 M).
iNOS = inducible nitric oxide synthase; LPS = lipopolysaccharide; RT-
PCR = reverse transcription polymerase chain reaction
Figure 3
Expression of iNOS protein in the alveolar macrophages was assessed
by western blot analysis with a monoclonal anti-iNOS antibody. LPS at
100 ng/ml stimulated the iNOS protein expression compared with
unstimulated alveolar macrophages. The iNOS protein was inhibited by
budesonide (10-4 M) and dexamethasone (10-4 M). iNOS = inducible
nitric oxide synthase; LPS = lipopolysaccharide
Figure 4
EMSA of NF-κ B complex. LPS (100 ng/ml) activated the NF-κ B expres-
sion after 30 min incubation compared with unstimulated alveolar mac-
rophages. The 32P-labeled oligonucleotide corresponding to a
consensus κ B site, the excessive cold NF-κ B probe and AP-1 probe
were incubated with 3 µg of nuclear protein. EMSA = electrophoretic
mobility shift assay; LPS = lipopolysaccharide; NF-κ B = nuclear factor-
kappaBRespiratory Research   Vol 3 No 1   Li et al.
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Abbreviations
CLD = chronic lung disease; DTT = dithiothreitol; EMSA = electro-
phoretic mobility shift assay; HEPES = HCO(3-)-free N-2-hydroxyethyl-
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inducible nitric oxide synthase; LPS = lipopolysaccaride; NF-κ B = nu-
clear factor-κ B; NO = nitric oxide; RT-PCR = reverse transcription – 
polymerase chain reaction; PMSF = phenylmethysulfonyl fluoride; TAF 
= tracheobronchial aspirate fluid
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